DESAIN VAKSIN HUMAN PAPILLOMAVIRUS TIPE 16 BERDASARKAN HUMAN LEUKOCYTE ANTIGEN POPULASI INDONESIA MELALUI PENDEKATAN REVERSE VACCINOLOGY
Cervical cancer is the second most common cancer case after breast cancer in Indonesia. About 50-60% of cancer cases are triggered by High Risk Human Papillomavirus (HR-HPV), HPV-16. Although vaccine can protect 70%-90% against the HR-HPV strain, the vaccine is not therapeutic virally infected pe...
Saved in:
| Main Author: | |
|---|---|
| Format: | Final Project |
| Language: | Indonesia |
| Online Access: | https://digilib.itb.ac.id/gdl/view/57963 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Institut Teknologi Bandung |
| Language: | Indonesia |
| Summary: | Cervical cancer is the second most common cancer case after breast cancer in
Indonesia. About 50-60% of cancer cases are triggered by High Risk Human
Papillomavirus (HR-HPV), HPV-16. Although vaccine can protect 70%-90%
against the HR-HPV strain, the vaccine is not therapeutic virally infected people.
This research aim to design a multi-epitope vaccine, for the Indonesian population,
which has both a therapeutic and prophylactic effect against HPV-16 from a
combination of E6, E7, and L1 proteins using a Reverse Vaccinlogy Indonesian
Human Leukocyte Antigen (HLA). 757 E7 sequences, 403 L1 sequences, and 2773
E6 sequences in NCBI determined each conserved region and analyzed the epitope
using a web server. As a result, we selected eight CD8+ T cell epitopes, four CD4+
T cell epitopes and three B cell epitopes of E7 and L1 protein epitopes. Then the
epitope linked with the adjuvant 50S ribosomal protein L7/L12 (rplL) from
Mycobacterium tuberculosis, PADRE sequence, and linker. Finally, we analyzed
the allergenicity antigenicity, physicochemical, 3D structure, and molecular
docking parameters. In addition, we found the vaccine candidate with a 99.99%
population coverage of Indonesian and predicted to have stable, hydrophilic,
antigenic, thermostable. The theoretical pI was 4.67, non-allergenic, and has a halflife
of about 1 hour in the human body. The ERRAT score is 91.56, the Z-score
value of -7.87, and the Ramachandra plot value of 96.3% shows a good result.
Furthermore, the interaction between vaccine candidate and Toll-Like Receptor
(TLR) 4 may occur, indicated by a negative G value and the presence of critical
residues. In summary, the vaccine candidate hopefully can induce a cellular
immune response in the body in the pre-clinical trial. |
|---|